376 related articles for article (PubMed ID: 29330256)
1. Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial.
Ueland T; Åkerblom A; Ghukasyan T; Michelsen AE; Aukrust P; Becker RC; Bertilsson M; Himmelmann A; James SK; Siegbahn A; Storey RF; Kontny F; Wallentin L;
J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29330256
[TBL] [Abstract][Full Text] [Related]
2. In-Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75 Years and Older With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Findings From the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome) Project.
Zhao G; Zhou M; Ma C; Huo Y; Smith SC; Fonarow GC; Ge J; Han Y; Liu J; Hao Y; Liu J; Wang X; Taubert KA; Morgan L; Zhao D; Nie S;
J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29602767
[TBL] [Abstract][Full Text] [Related]
3. Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.
Lindholm D; Hagström E; James SK; Becker RC; Cannon CP; Himmelmann A; Katus HA; Maurer G; López-Sendón JL; Steg PG; Storey RF; Siegbahn A; Wallentin L
J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28411246
[TBL] [Abstract][Full Text] [Related]
4. Risk of Major Bleeding With Potent Antiplatelet Agents After an Acute Coronary Event: A Comparison of Ticagrelor and Clopidogrel in 5116 Consecutive Patients in Clinical Practice.
Mullen L; Meah MN; Elamin A; Aggarwal S; Shahzad A; Shaw M; Hasara J; Rashid M; Fisher M; Ali T; Patel B; Ding WY; Grainger R; Heseltine T; Kirmani BH; Obeidat M; Kasolo Y; Thatchil J; Khand A
J Am Heart Assoc; 2021 Apr; 10(8):e019467. PubMed ID: 33834845
[TBL] [Abstract][Full Text] [Related]
5. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
James S; Budaj A; Aylward P; Buck KK; Cannon CP; Cornel JH; Harrington RA; Horrow J; Katus H; Keltai M; Lewis BS; Parikh K; Storey RF; Szummer K; Wojdyla D; Wallentin L
Circulation; 2010 Sep; 122(11):1056-67. PubMed ID: 20805430
[TBL] [Abstract][Full Text] [Related]
6. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Andell P; James SK; Cannon CP; Cyr DD; Himmelmann A; Husted S; Keltai M; Koul S; Santoso A; Steg PG; Storey RF; Wallentin L; Erlinge D;
J Am Heart Assoc; 2015 Oct; 4(10):e002490. PubMed ID: 26452988
[TBL] [Abstract][Full Text] [Related]
7. Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study.
Lindholm D; James SK; Gabrysch K; Storey RF; Himmelmann A; Cannon CP; Mahaffey KW; Steg PG; Held C; Siegbahn A; Wallentin L
JAMA Cardiol; 2018 Dec; 3(12):1160-1166. PubMed ID: 30427997
[TBL] [Abstract][Full Text] [Related]
8. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.
Tomaniak M; Chichareon P; Onuma Y; Deliargyris EN; Takahashi K; Kogame N; Modolo R; Chang CC; Rademaker-Havinga T; Storey RF; Dangas GD; Bhatt DL; Angiolillo DJ; Hamm C; Valgimigli M; Windecker S; Steg PG; Vranckx P; Serruys PW;
JAMA Cardiol; 2019 Nov; 4(11):1092-1101. PubMed ID: 31557763
[TBL] [Abstract][Full Text] [Related]
9. Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.
Deharo P; Quilici J; Camoin-Jau L; Johnson TW; Bassez C; Bonnet G; Fernandez M; Ibrahim M; Suchon P; Verdier V; Fourcade L; Morange PE; Bonnet JL; Alessi MC; Cuisset T
JACC Cardiovasc Interv; 2017 Dec; 10(24):2560-2570. PubMed ID: 29268886
[TBL] [Abstract][Full Text] [Related]
10. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.
Baber U; Leisman DE; Cohen DJ; Gibson CM; Henry TD; Dangas G; Moliterno D; Kini A; Krucoff M; Colombo A; Chieffo A; Sartori S; Witzenbichler B; Steg PG; Pocock SJ; Mehran R
Circ Cardiovasc Qual Outcomes; 2019 Jan; 12(1):e004945. PubMed ID: 30606052
[TBL] [Abstract][Full Text] [Related]
11. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study.
Hagström E; James SK; Bertilsson M; Becker RC; Himmelmann A; Husted S; Katus HA; Steg PG; Storey RF; Siegbahn A; Wallentin L;
Eur Heart J; 2016 Apr; 37(16):1325-33. PubMed ID: 26417057
[TBL] [Abstract][Full Text] [Related]
12. Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial.
Park DW; Kwon O; Jang JS; Yun SC; Park H; Kang DY; Ahn JM; Lee PH; Lee SW; Park SW; Choi SW; Lee SG; Yoon HJ; Ahn T; Kim MH; Nah DY; Lee SY; Chae JK; Park SJ;
Circulation; 2019 Dec; 140(23):1865-1877. PubMed ID: 31553203
[TBL] [Abstract][Full Text] [Related]
13. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Husted S; James S; Becker RC; Horrow J; Katus H; Storey RF; Cannon CP; Heras M; Lopes RD; Morais J; Mahaffey KW; Bach RG; Wojdyla D; Wallentin L;
Circ Cardiovasc Qual Outcomes; 2012 Sep; 5(5):680-8. PubMed ID: 22991347
[TBL] [Abstract][Full Text] [Related]
14. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
Kohli P; Wallentin L; Reyes E; Horrow J; Husted S; Angiolillo DJ; Ardissino D; Maurer G; Morais J; Nicolau JC; Oto A; Storey RF; James SK; Cannon CP
Circulation; 2013 Feb; 127(6):673-80. PubMed ID: 23277305
[TBL] [Abstract][Full Text] [Related]
15. Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial.
Brilakis ES; Held C; Meier B; Cools F; Claeys MJ; Cornel JH; Aylward P; Lewis BS; Weaver D; Brandrup-Wognsen G; Stevens SR; Himmelmann A; Wallentin L; James SK
Am Heart J; 2013 Sep; 166(3):474-80. PubMed ID: 24016496
[TBL] [Abstract][Full Text] [Related]
16. Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y
Franchi F; James SK; Ghukasyan Lakic T; Budaj AJ; Cornel JH; Katus HA; Keltai M; Kontny F; Lewis BS; Storey RF; Himmelmann A; Wallentin L; Angiolillo DJ;
J Am Heart Assoc; 2019 Mar; 8(6):e011139. PubMed ID: 30857464
[TBL] [Abstract][Full Text] [Related]
17. Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice: Results From the Bern Percutaneous Coronary Intervention Registry.
Zanchin T; Temperli F; Karagiannis A; Zanchin C; Räsänen M; Koskinas KC; Stortecky S; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Billinger M; Heg D; Pilgrim T; Valgimigli M; Windecker S; Räber L
Circ Cardiovasc Interv; 2018 May; 11(5):e006132. PubMed ID: 29748219
[TBL] [Abstract][Full Text] [Related]
18. Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Åkerblom A; Wojdyla DM; Wallentin L; James SK; de Souza Brito F; Steg PG; Cannon CP; Katus HA; Himmelmann A; Storey RF; Becker RC; Lopes RD;
Am Heart J; 2019 Jul; 213():57-65. PubMed ID: 31108273
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.
Wallentin L; Lindholm D; Siegbahn A; Wernroth L; Becker RC; Cannon CP; Cornel JH; Himmelmann A; Giannitsis E; Harrington RA; Held C; Husted S; Katus HA; Mahaffey KW; Steg PG; Storey RF; James SK;
Circulation; 2014 Jan; 129(3):293-303. PubMed ID: 24170388
[TBL] [Abstract][Full Text] [Related]
20. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
